Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Inclusion Criteria:

* Measurable unresectable Stage III or Stage IV melanoma
* ECOG Performance Status 0 or 1
* 4 weeks or greater since treatment
* Must have recovered from any acute toxicity associated with prior therapy
* Life expectancy of greater than 12 weeks
* 18 years of age or older
* Laboratory values as outlined in protocol
* Negative screening tests for HIV, active Hepatitis B and Hepatitis C
* Patients who received prior therapy with anthracyclines should have a baseline MUGA or echo with a normal ejection fraction

Exclusion Criteria:

* CNS metastases
* Pregnant or nursing women
* Prior therapy with bevacizumab or ipilimumab
* Active infection
* Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic autoimmune disease
* Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
* Any underlying medical condition which, in the principal investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events
* Any concurrent medical condition requiring the use of systemic steroids
* Inadequately controlled hypertension
* Any prior history of hypertensive crisis or hypertensive encephalopathy
* NYHA Grade II or greater congestive heart failure
* History of myocardial infarction or unstable angina within 6 months prior to study enrollment
* History of stroke of transient ischemic attack within 6 months prior to study enrollment
* Significant known vascular disease
* Symptomatic peripheral vascular disease
* Evidence of bleeding diathesis or coagulopathy
* Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment
* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
* Serious, non-healing wound, ulcer or bone fracture
* Proteinuria at screening
* Known hypersensitivity to any component of bevacizumab
* History of hemoptysis within 3 months prior to study enrollment
* Current, ongoing treatment with full-dose warfarin or its equivalent
* Current or recent (within 10 days of enrollment) use of aspirin (\>325mg/day) or chronic use of other NSAIDs
* Medications that inhibit platelet function
* Known involvement of melanoma within gastrointestinal tract
* Ulcerated skin lesions